

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/895,072	07/02/2001	William M. Canfield	210119US0CONT 3250	
22850 7	7590 06/14/2002			
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VA 22202			EXAMINER	
			PATTERSON, CHARLES L JR	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	VII 22202		ART UNIT	PAPER NUMBER
			1652	
			DATE MAILED: 06/14/2002	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/895,072	CANFIELD, WILLIAM M.				
Office Action Summary	Examin r	Art Unit				
	Charles L. Patterson, Jr.	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on	·					
2a) This action is FINAL . 2b) T	his action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) Claim(s) 1-24 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-24</u> are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)				
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office A	ction Summary	Part of Paper No. 4				

Application/Control Number: 09/895,072

Art Unit: 1652

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5, 7-8 and 10-11, drawn to a method for preparing a highly phosphorylate α -glucosidase using a GlcNAc-phosphotrans-ferase of SEQ ID NO: 1-3 and a pharmaceutical composition, classified in class 435, subclass 200.
- II. Claims 1-5 and 9, drawn to a method for preparing a highly phosphorylated α -glucosidase using a GlcNAc-phosphotransferase of SEQ ID NO: 15, 8 and 9 and a pharmaceutical composition, classified in class 435, subclass 200.
- III. Claim 6, drawn to a method of treating Pompe's disease using the pharmaceutical composition of Groups I or II, classified in class 424, subclass 945.61.
- IV. Claims 12-18, 20-21 and 23-24, drawn to a method of producing a highly phosphorylated α -glucosidase comprising using a GlcNAc-phosphotransferase of SEQ ID NO:1-3 and an α 1,2-mannosidase inhibitor, a highly phosphorylated α -glucosidase and a pharmaceutical composition, classified in class 435, subclass 200.
- V. Claims 12-18 and 22, drawn to a method of producing a highly phosphorylated α -glucosidase comprising using GlcNAc-phosphotrans-ferase of SEQ ID NO:15, 8 and 9 and an α 1,2-mannosidase inhibitor and a pharmaceutical composition, classified in class 435, subclass 200.
- VI. Claim 19, drawn to a method of treating Pompe's disease using the pharmaceutical composition of Groups IV or V, classified in class, subclass.

The inventions are distinct, each from the other because:

Application/Control Number: 09/895,072

Art Unit: 1652

The methods of Groups (I, and II) and (IV and V) are drawn to different processes using different components. The methods of Groups I and II and the methods of Groups IV and V are separate and distinct because the SEQ ID Nos are separate and distinct proteins that are structurally different.

Inventions (I, II) and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the enzyme can be used for its enzymatic activity, not related to treating Pompe's disease.

Inventions (IV, V) and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the enzyme can be used for its enzymatic activity, not related to treating Pompe's disease.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 4

Application/Control Number: 09/895,072

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 703-308-1834. The examiner can normally be reached on Monday - Friday, 7:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Charles L. Patterson, Jr Primary Examiner

Art Unit 1652

Patterson June 13, 2002